For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

29th Sep 11

Phase II Trial in Subjects with Allergic Asthma Completes Enrolment

Pharmaxis today announced it has completed enrolment of all subjects into its Phase II clinical trial evaluating ASM8, a potential new treatment for patients with moderate to severe asthma.


Read full media release - pdf
22nd Aug 11

Re-examination Documents Submitted for EU Bronchitol Marketing Application

Pharmaxis today announced that it had submitted detailed grounds for re-examination of its Bronchitol EU marketing application for cystic fibrosis to the Committee for Medicinal Products for Human Use.The documents have been lodged following the formal request for re-examination submitted last month and subsequent dialogue between the Company and the new Rapporteurs appointed to lead the process.


Read full media release - pdf
12th Jul 11

Bronchitol Resubmitted to Australian Pharmaceuticals Benefits Advisory Committee

Pharmaxis today announced that it has resubmitted an application for its cystic fibrosis product Bronchitol to the Pharmaceutical Benefits Advisory Committee for reimbursement on the Australian Pharmaceutical Benefits Scheme.


Read full media release - pdf